Sugi Predict

Sugi Predict / Compounds / SCHEMBL2908859

SCHEMBL2908859

SCHEMBL2908859

O=C(CCc1cccc(OCc2ccccc2)c1)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 5/20 0.64
▸ CYP4F2 P78329 1/20 0.63
▸ CYP4A11 Q02928 1/20 0.63
▸ NR4A2 P43354 1/20 0.57
▸ MAOB P27338 1/20 0.55
▸ FFAR4 Q5NUL3 2/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ CYP2D6 P10635 1/20 0.53
▸ TSHR P16473 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ SMPD1 P17405 1/20 0.52
▸ LTB4R Q15722 1/20 0.52
▸ LTB4R2 Q9NPC1 1/20 0.52
▸ BCHE P06276 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ SRD5A2 P31213 1/20 0.51
▸ MGLL Q99685 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8350924 0.92 CYP4F2 (0.60) FFAR1CYP4F2CYP4A11NR4A2MAOB
SCHEMBL10733098 0.90 FFAR1 (0.60) FFAR1CYP4F2CYP4A11NR4A2MAOB
SCHEMBL10683288 0.87 FFAR1 (0.63) FFAR1CYP4F2CYP4A11NR4A2MAOB
SCHEMBL2772855 0.86 FFAR1 (0.83) FFAR1CYP4F2CYP4A11NR4A2FFAR4
SCHEMBL7998538 0.86 FFAR1 (0.69) FFAR1CYP4F2CYP4A11NR4A2MAOB
SCHEMBL18003447 0.86 MAOB (0.59) FFAR1CYP4F2CYP4A11NR4A2MAOB
SCHEMBL1137350 0.85 ALDH1A1 (0.67) FFAR1CYP4F2CYP4A11NR4A2MAOB
SCHEMBL7276062 0.85 FFAR1 (0.74) FFAR1NR4A2FFAR4TDP1
Phenyl Propionic Acid SCHEMBL1564075 0.85 FFAR1 (0.64) FFAR1NR4A2FFAR4TDP1
SCHEMBL1564073 0.84 FFAR1 (0.56) FFAR1CYP4F2CYP4A11NR4A2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834515-B2 Macrocyclic compounds as proteasome inhibitors CORNELL UNIVERSITY (US) 2023-12-05 — — US disclosed
US-11834515-B2 Macrocyclic compounds as proteasome inhibitors CORNELL UNIVERSITY (US) 2023-12-05 — — US disclosed
CN-107207444-B Bicyclic compounds 武田药品工业株式会社 2020-07-24 — — CN disclosed
EP-3225618-B1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-05-06 — — EP disclosed
US-10301292-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-28 — — US disclosed
WO-2019075259-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS CORNELL UNIVERSITY (US) 2019-04-18 — — WO disclosed
US-20180002322-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-01-04 — — US disclosed
EP-3225618-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-10-04 — — EP disclosed
CN-107207444-A Bicyclic compound 武田药品工业株式会社 2017-09-26 — — CN disclosed
US-20100273770-A1 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES GLAXO GROUP LIMITED (GB) 2010-10-28 — — US disclosed
EP-2044063-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Astra Zeneca AB (SE) 2009-04-08 — — EP disclosed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 — — WO disclosed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 — — US disclosed
US-7115658-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase AGOURON PHARMACEUTICALS, INC. (US) 2006-10-03 — — US disclosed
US-20040023958-A1 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same AGOURON PHARMACEUTICALS, INC. 2004-02-05 — — US disclosed
WO-2003095441-A1 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2003-11-20 — — WO disclosed
EP-0483667-B1 Cyclic imino derivatives, process for their preparation and drugs containing them THOMAE GMBH DR K (DE) 1998-02-04 — — EP disclosed
US-5591769-A PYRROLIDINE DERIVATIVES; ANTICOAGULANTS KARL THOMAE GMBH (DE) 1997-01-07 — — US disclosed
US-5541343-A ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS KARL THOMAE GMBH (DE) 1996-07-30 — — US disclosed
EP-0483667-A2 Cyclic imino derivatives, process for their preparation and drugs containing them Dr. Karl Thomae GmbH (DE) 1992-05-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273770-A1 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES SSB, RORC, OXA1L FFAR1 1971/4885CYP4F2 664/4885CYP4A11 155/4885
US-20180002322-A1 BICYCLIC COMPOUND ACACA, ACACB, ACAT1 FFAR1 3146/4885CYP4F2 1394/4885CYP4A11 881/4885
US-10301292-B2 Bicyclic compound ACACA, ACACB, ACAT1 FFAR1 3146/4885CYP4F2 1394/4885CYP4A11 881/4885
US-11834515-B2 Macrocyclic compounds as proteasome inhibitors PSMB5, PSMB1, PSMB3 FFAR1 3192/4885CYP4F2 3856/4885CYP4A11 3435/4885
US-20040023958-A1 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same POLRMT, RNGTT, RNASE1 FFAR1 3595/4885CYP4F2 1947/4885CYP4A11 1821/4885
US-20080004302-A1 Novel Compounds CYP11B2, CYP11B1, CYP46A1 FFAR1 1591/4885CYP4F2 35/4885CYP4A11 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.